Metropolis Healthcare Q2FY27 Results: Revenue rises 15% YoY on volume growth
- Revenue grew 15% YoY in Q2FY27 driven by double-digit patient and test volume growth
- TruHealth Wellness and Specialty segments emerged as the fastest-growing verticals
- EBITDA margins expanded on both YoY and QoQ basis due to operating leverage
- Improved realizations and favorable product mix contributed to revenue increase
*this image is generated using AI for illustrative purposes only.
Metropolis Healthcare reported a 15% year-over-year rise in revenue for Q2FY27, supported by strong growth in patient volumes and test volumes, alongside an expansion in EBITDA margins.
Revenue and volume performance
The 15% YoY revenue growth in Q2FY27 was driven by robust patient and test volume growth. The improvement in both volume metrics points to increased utilisation across Metropolis Healthcare's diagnostic network during the quarter. Additionally, the company cited improved realizations and a change in product mix as contributing factors to the topline expansion.
Segment-specific growth drivers
During the quarter ended September 30, 2026, the TruHealth Wellness and Specialty segments emerged as the fastest-growing verticals for the company. This segment-level detail provides further granularity on where the demand trends were strongest within the broader diagnostic business.
EBITDA margin expansion
Alongside topline growth, Metropolis Healthcare also recorded an improvement in EBITDA margins during Q2FY27. The margin expansion occurred on both a year-over-year and quarter-over-quarter basis, driven by operating leverage and efficiency gains within the business.
| Metric | Q2FY27 Status | Driver |
|---|---|---|
| Revenue growth (YoY) | +15% | Volume, realizations, mix |
| Patient volume growth | Strong | Increased utilisation |
| Test volume growth | Strong | Increased utilisation |
| EBITDA margins | Expanded | Operating leverage, efficiency |
Key highlights
- Revenue rose 15% YoY in Q2FY27
- Growth was driven by double-digit patient and test volume increases
- TruHealth Wellness and Specialty segments were the fastest-growing segments
- EBITDA margins expanded meaningfully on both YoY and QoQ basis
Metropolis Healthcare's Q2FY27 performance reflects broad-based volume momentum across its diagnostics business, with both patient footfall and test throughput contributing to the revenue uptick and supporting margin improvement.
Historical Stock Returns for Metropolis Healthcare
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +2.92% | -5.03% | -4.92% | +30.49% | +8.49% | -20.39% |
How sustainable is the current EBITDA margin expansion given potential inflationary pressures on medical supplies and labor costs in upcoming quarters?
What specific capacity constraints or capital expenditure plans are required to support the rapid growth in the TruHealth Wellness and Specialty segments?
To what extent will the improved product mix and realizations continue to drive revenue growth as competitive pricing pressures intensify in the diagnostic sector?
19
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
